Praxis Precision News Today

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $105.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 91.61% from the company’s previous close. PRAX […]

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) traded down 6.1% on Wednesday . The company traded as low as $51.82 and last traded at $52.18. 81,782 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 213,917 shares. The stock had previously closed at $55.57. […]

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $105.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 77.54% from the stock’s current price. A […]

Shares of Praxis Precision Medicines, Inc. (PRAX) jumped over 26% on Tuesday morning after the company reported positive results from a phase 2 study of epilepsy treatment.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its target price boosted by equities researchers at Jefferies Financial Group from $75.00 to $128.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective points to a potential upside […]

Key Insights Using the 2 Stage Free Cash Flow to Equity, Praxis Precision Medicines fair value estimate is US$59.16...

Key Insights Institutions' substantial holdings in Praxis Precision Medicines implies that they have significant...

/PRNewswire/ -- Deka Biosciences ("Deka") today announced the appointments of Stanley Frankel, M.D., FACP, as senior clinical advisor, interim chief medical...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 3,460,000 shares, a growth of 25.4% from the October 31st total of 2,760,000 shares. Based on an average trading volume of 737,900 shares, the short-interest […]

Praxis Precision Medicines, Inc. ( NASDAQ:PRAX ) insiders who acquired shares over the previous 12 months, can probably...